Preclinical AD Clinical Measurement Presents Unique Trial Challenges
Alzheimer’s disease progresses along a disease continuum with an extended preclinical stage defined by individuals showing amyloid positivity but with normal functional status.
In clinical trials for preclinical AD, the participant characteristics, outcome measures, assessment procedures, and context of assessments require substantially different strategies to those in symptomatic AD. Many scales commonly used to measure cognitive change in other neurodegenerative conditions lack the sensitivity to capture subtle changes associated with preclinical AD so it’s important to carefully consider endpoint approaches.
Cogstate has the hands-on experience to support the unique approaches necessary to reduce patient and site burden and capture quality data in your preclinical AD trial.
